Skip to main content
Premium Trial:

Request an Annual Quote

Roche ALK Test Gains FDA Approval as CDx for Alecensa

NEW YORK (360Dx) –  Roche said today that the US Food and Drug Administration has approved its Ventana ALK (D5F3) companion diagnostic as an aid in identifying ALK-positive non-small cell lung cancer patients who would benefit from treatment with the firm's drug Alecensa (alectinib).

"This immunohistochemistry assay will deliver critical information on treatment options for non-small cell lung cancer patients," Ann Costello, head of Roche tissue diagnostics, said in a statement. "The ability to identify ALK-positive patients very quickly with a simple IHC test ensures that more patients can benefit from targeted therapy."

The detection and inhibition of the ALK biomarker found in NSCLC can help shrink tumors in some ALK-positive patients, the firm added.

The Ventana ALK (D5F3) CDx is available for use on the Roche BenchMark XT or BenchMark Ultra IHC/ISH slide staining systems.

The ALK test also gained FDA approval in June 2017 as a CDx to identify best responders to Novartis' NSCLC drug Zykadia (ceritinib) in June 2017, and gained FDA approval in June 2015 as a CDX to identify NSCLC patients who are likely to respond well to Pfizer's Xalkori (crizotinib).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.